The agreement with Palatin follows a $1bn deal with Re-Vana earlier this year as Boehringer targets the ophthalmology market.

Palatin has a research program in DR, and more specifically, in diabetic macular edema (DME), a complication of DR that ...

Medically reviewed by Erika Prouty, PharmD While Ozempic (semaglutide) can help manage blood sugar in type 2 diabetes or ...

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

Fully autonomous screening for diabetic retinopathy is coming to pharmacies and other locations through a strategic ...

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic retinopathy (DR) and with a ...

However, left untreated, diabetic retinopathy will steadily get worse over time and start to affect your vision. Treatment can help prevent, delay, and reduce vision loss.

Diabetic retinopathy and diabetic macular edema (DME) are two of the most common vision conditions related to diabetes. They affect about 1 in 4 people with type 1 and type 2 diabetes.

Regarding diabetic retinopathy’s prevalence, , there are 40 million Americans who have diabetes, and about 60% of them of them will go on to get diabetic eye disease.

Diabetic retinopathy, a type of diabetic eye disease, is one of the leading causes of blindness in the United States. Despite this, almost 40% of people with diabetes don’t get an annual eye exam.